Clinical Implication of High Sensitivity C-Reactive Protein for the Development of Dementia in Parkinson's Disease.
10.12779/dnd.2015.14.3.123
- Author:
Sung Jin PARK
1
;
In Uk SONG
;
Sung Woo CHUNG
;
Youngsoon YANG
Author Information
1. Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea. siuy@cmcnu.or.kr
- Publication Type:Original Article
- Keywords:
Parkinson's disease;
dementia;
C-reactive protein
- MeSH:
C-Reactive Protein*;
Dementia*;
Humans;
Inflammation;
Parkinson Disease*
- From:Dementia and Neurocognitive Disorders
2015;14(3):123-127
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND PURPOSE: High-sensitivity C-reactive protein (hs-CRP) is the most widely studied biomarker of systemic inflammation. Its level has been reported to be associated with cognitive impairment. While dementia and cognitive impairment are common non-motor symptoms in advanced idiopathic Parkinson's disease (PD), the clinical value of hs-CRP for predicting dementia in PD patients remains unclear. Therefore, the objective of this study was to clarify the relationship between hs-CRP levels and the development or progression of dementia in PD through evaluating hs-CRP levels in PD patients with or without dementia. METHODS: A total of 112 PD patients without dementia (PD-D), 103 PD patients with dementia (PD+D), and 94 healthy controls were used in this study. The levels of hs-CRP and cognitive function were analyzed among these three groups. RESULTS: The mean serum hs-CRP levels in PD-D and PD+D were 1.76+/-3.62 mg/dL and 1.44+/-2.78 mg/dL, respectively, which were significantly (p=0.02) higher than that (vs. 0.41+/-1.06 mg/dL) in healthy controls. However, the levels of hs-CRP were not significantly (p>0.05) different between PD-D and PD+D. CONCLUSIONS: Our results suggest that neuro-inflammation plays a role in the pathogenesis of PD. However, it does not significantly contribute to the development or the progression of dementia in PD patients.
